Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 20Lymphoma, Follicular 13Waldenstrom Macroglobulinemia 12Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 11Lymphoma, B-Cell 10Leukemia 9Recurrence 8Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphoid 4Leukemia, B-Cell 4Hodgkin Disease 4Bronchiolitis Obliterans Syndrome 4Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Neoplasms 2Lung Neoplasms 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Acute 2Graft vs Host Disease 2Chromosome 17 deletion 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1

Interventions

Everolimus 16Octreotide 6pembrolizumab 5lanreotide 5Sunitinib 5Magnetic Resonance Spectroscopy 5gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3lenvatinib 3arginyllysine 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2pasireotide 2lutetium Lu 177 dotatate 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroendocrine Tumors × ibrutinib × Clear all
NCT02575300 2020-09-11

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
20 enrolled 11 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡